Eugenia Cogliandro, chemical officer and coordinator for the quality aspects of AIFA’s Medicinal Products Authorisation Division and Italian delegate at the EMA's Joint CHMP/CVMP Quality Working Party (QWP), has been elected Chair of the European Pharmacopoeia Commission (EPC), the decision-making body of the European Pharmacopoeia. She will take up her duties during the 182nd session of the EPC on 17 June 2025, for a three-year term.      
“This assignment is an important personal achievement and a success for Italy. It is the recognition of AIFA’s skills and professionalism, which confirms its leading role in the European regulatory network – said President Robert Nisticò – I congratulate Eugenia Cogliandro and wish her every success in her work.” 

Eugenia Cogliandro, a member of the Italian delegation to the EPC since 2009, was appointed first Vice-Chair of the EPC in 2022 for a three-year mandate. She contributed to achieving the mission of the European Pharmacopoeia by ensuring access to medicines of adequate quality. 

"The European Pharmacopoeia - says Cogliandro - promotes the protection of public health by providing harmonised quality standards for the safe use of medicines. It is widely used all over the world; this global impact, coupled with the opportunity to contribute to one of the fundamental human rights of access to high-quality medicines, makes me particularly honoured to be in this post in continuity with my role as First Vice-Chair for the past three years, during which important results have been achieved. In particular, the EPC has further demonstrated its commitment to animal welfare and has abolished from the European Pharmacopoeia all general safety tests involving the use of animals in the quality control of medicinal products, replacing them with more ethical alternatives." 

"The publication of the twelfth edition this year, which will enter into force on 1 January 2026, marks the beginning of a new era for the European Pharmacopoeia, as it will be available exclusively online. This transition reflects ongoing scientific and technological advancements, as well as a strong commitment to environmental sustainability.

The accomplishments of the European Pharmacopoeia are the result of the dedication and collaborative efforts of the entire expert community involved in its development. I am deeply proud to have contributed to this work since 2009, and even more so now in my role as Chair of the Commission."